Join us for our upcoming seminar, “From Bench to Bedside: Accelerating Early Drug Development with an Integrated, Multi-Phase Development Partner”. Taking place in Copenhagen on 16th October, this event will explore the critical transition of a new drug from candidate nomination through to proof of concept studies, highlighting the scientific and operational strategies that drive successful early-phase programs.
The opening presentation, led by Dr. Andrew Parker, Senior Drug Development Consultant, will delve into the preclinical-to-first-in-human (FIH) transition, emphasizing the role of predictive modelling in risk assessment, solubility profiling, and formulation screening. Practical application of these insights will be demonstrated through examples from Quotient Sciences, which enables more informed early-stage decisions.
Following this, John McDermott, VP of Scientific Consulting, will address formulation selection and drug product supply strategies, for the first-in-human protocol. The session will discuss the implementation of innovative drug development strategies, supported by real-world examples of Translational Pharmaceutics® in accelerating the journey from FIH to PoC. It will explore how integrated patient supply solutions—like adaptive manufacturing processes that ensure rapid clinical supply changes—can streamline program execution and enhance flexibility throughout early clinical trials.
This seminar is exclusive in access to industry experts and innovative methodologies. Interactive Q&A sessions with leading scientists from Quotient Sciences will provide attendees with direct insights and practical solutions to common early-phase challenges. By blending expert guidance with actionable case studies, the event offers a unique opportunity to optimize molecule readiness and delivery in early clinical development.
Date: Thursday, 16th October 2025
Time: 9:30 – 14:00
Venue: Symbion Science Park, Fruebjergvej 3, Copenhagen Ø, Demark